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ABSTRACT  
In the current scenario type two diabetes mellitus and hypertension have become prevalent in large number of population. But there are many 
patients which are suffering from Type II Diabetes Mellitus as well as hypertension. Such condition is called co-existent Type II Diabetes 
Mellitus and Hypertension. In the present work an attempt is made to treat co-existent type II Diabetes Mellitus and hypertension by 
formulating a Bilayer tablet of Teneligliptin and Telmisartan. Both drugs are sustained released to give a day long relief to the patients and to 
also reduce the dose frequency. Both the layers of the tablets were formulated by wet granulation method. The granules were tested for angle of 
repose, bulk density, tapped density, compressibility and Hausner’s ratio to check their efficacy. Eleven different types of formulations were 
made using various polymers and excipients with the drugs such as PVP K30, HPMC K4M, Starch, Crospovidone, Lactose, Mannitol,  Talc and 
Magnesium Stearate. From these 11 formulations F6 showed better tablet characteristics and drug release rate than other formulations. Thus 
F6 is the best formulation in this study. Biological screening of the drugs combination of Teneligliptin and Telmisartan was also done to check 
the presence of antidiabetic activity of the combination which showed positive results. 
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INTRODUCTION: 
In this modern world of faster and hectic lives, eating 
healthy and staying fit is ignored. Such ignorance may lead 
to various harmful diseases and disorders. Diabetes 
mellitus is such kind of disorder which if not managed 
properly may prove fatal. Type II Diabetes mellitus is the 
most harmful type of diabetes as the body of the patient 
becomes insulin resistant. Also hypertension is present in 
large number of populations. But when these two severe 
diseases are present coexistently in an individual, 
additional care is needed to be taken. Coexistent Type Two 
Diabetes Mellitus (TTDM) and hypertension exposes 
patients to severe co-morbidities.     
Hypertension (HTN) is present in more than 50% of 
patients with diabetes mellitus (DM) and contributes 
significantly to both micro and macrovascular disease in 
DM. Indeed, the risk for cardiovascular disease (CVD) is 
four-fold higher in patients with both DM and HTN as 
compared to the normotensive non-diabetic controls. To 
this point, a meta-analysis of 102 prospective studies 
involving 698,782 individuals found that DM is responsible 
for approximately a two-fold increased risk for coronary 
heart disease, stroke and deaths from cardiovascular 
cause, including heart failure, cardiac arrhythmia, 
hypertensive disease, etc. In developed countries 60-65% 
prevalence is seen in coexistent type II diabetes mellitus 
and hypertension. Complex polypharmacy suggested by 
international organizations leads to the increased pill 
burden and decreased patient compliance which leads to 
worsening of conditions1,2.     
Hence there is a need for a combination of antidiabetic and 
antihypertensive drugs for the treatment of coexistent 
type two diabetes mellitus and hypertension. 
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MATERIALS:- 
Teneligliptin was provided as gift sample from Lupin 
Pharmaceuticals Limited, Pune whereas Telmisartan was 
obtained from Abbott Healthcare Pvt. Ltd. Himachal 
Pradesh as gift samples. Polymers and excipients such as 
HPMC K4M, PvpK30, crospovidone, talc etc were 
purchased from JP. Fine chemicals and Loba Chemise Pvt. 
Ltd. 
METHODS:- 
Various techniques can be used to formulate bilayer 
tablets. Wet granulation is one of the techniques used to 
formulate the two layers of tablets. Wet granules of both 
layers are formulated individually. Wet granulation 
techniques have various advantages. Hence it is a method 
of choice for many tablet formulations. It enhances the 
flow properties of powder mix. It avoids segregation of 
powder components during tabletting or storage. It also 
reduces cross-contamination and hazard associated with 
the generation of toxic dust that may arise during 
manufacturing process. Wet granulation not only improves 
the compression characteristics of drug substances as well 
as improves the appearance of the final product. Wet 
granulation involves use of water for granulation. Aqueous 
binder solution is added to the dough mass and then 
sieved to produce the required size of granules. Tablets 
made from wet granulation techniques have better 
hardness and appearance then directly compressed 
tablets. Conventional equipment, commonly available 
excipients and a limited number of processing steps are 
involved in direct compression. Also high doses can be 
accommodated. Moreover this technique improves the 
dissolution characteristics of the poorly water-soluble 
drugs by allowing uniform distribution of the binder that 
acts as a wetting agent and enable adequate wetting of the 
drug substance during granulation. It also increases the 
chances of adequate and uniform contact between the drug 
and hydrophilic polymer for better dissolution. These 
improved granule characteristics also results in even 
erosion of tablets during dissolution (4,15). 
 
 
 
 Preparation of Tablet by Wet Granulation :  
 Wet Granulation of Sustained Release 
Telmisartan Layer :- 
Wet granulation is the most widely used to prepare tablets. 
Formulation with different binders was compressed into 
tablets. The required quantities of Telmisartan ,starch 
,lactose monohydrate ,HPMC K4M, crospovidone were 
weighed accurately using analytical balance and were 
mixed well using laboratory conditions. The aqueous 
binder solution was added and mixed thoroughly to form 
dough mass. Carmiosine Colour was added to the aqueous 
binder solution for Telmisartan granules to provide visual 
detection of two different layers in the bilayer tablets. The 
formed mass was passed through Mesh no.12 to obtain 
wet granules .The wet Granules were dried in a hot air 
oven at 300 c temperatures. then the dried granules were 
passed through mesh no.16 to break aggregates. Talc & 
magnesium stearate were passed through mesh no.100 on 
to dry granules and blended in a polyethylene bag .The 
Tablet granules were then compressed using compression 
machine at punch No. 5 (11,15). 
 Wet Granulation of Sustained Release 
Teneligliptin Layer :- 
Wet granulation is done for this layer of Bilayer tablet too. 
This layer consists of drug/API. Teneligliptin(20mg) and 
various excipients which act as binders, diluents and 
lubricants in the formulation. These are starch, mannitol 
and magnesium stearate respectively. HPMC K4M is the 
sustained releasing agent. The aqueous binder solution 
was added and mixed thoroughly to form a dough mass. 
The formed dough mass was passed through Mesh no.12 to 
obtain wet granules of Teneligliptin layer. The wet 
granules were dried in a hot air oven at 300 oc 
temperatures. On drying, the dried granules were passed 
through mesh no.16 to break aggregates if formed. Talc & 
magnesium stearate were passed through mesh no.100 on 
to dry granules and blended in the polyethylene bag kept 
for these granules. The Tablet granules were then 
compressed using compression machine at punch No. 5 
over the Telmisartan layer. 
Thus, The Bilayer Tablet is formed by the Above 
Mentioned Processes 
 
Compositions of Bilayer Tablets 
Table No.1: Compositions of Sustained Release Layer of Teneligliptin :- 
Sr. 
No. 
Ingredient mg/Tablet F1 F2 F3 F5 F4 F6 F7 F8 F9 F10 F11 
1 Teneligliptin 20 20 20 20 20 20 20 20 20 20 20 
2 HPMC K4M 105 105 105 105 53 105 105 105 105 105 105 
3 PVP K30 20 - - - - - - - - - - 
4 Starch 55 55 55 82 55 82 82 55 55 55 55 
5 Lactose 34 54 - 27 106 - 07 - 44 34 24 
6 Mannitol - - 54 - - 27 - 34 - - - 
7 Crosspovidone - - - - - - 20 20 10 20 30 
8 Magnesium Stearate 3 3 3 3 3 3 3 3 3 3 3 
9 Talcum 3 3 3 3 3 3 3 3 3 3 3 
10 P. Water Q.S. Q.S. QS QS Q.S QS. QS. QS Q.S Q.S Q.S 
 Total Weight 240 240 240 240 240 240 240 240 240 240 240 
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Table No.2 : Compositions of Sustained Release Layer of Telmisartan :- 
Sr. 
No. 
Ingredient 
mg/Tablet 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 
1 Telmisartan 40 40 40 40 40 40 40 40 40 40 40 
2 HPMC K4M 105 105 105 53 105 105 157 105 105 105 105 
3 PVP K30 40 - - - - - - - - - - 
4 Starch 55 55 55 55 27 27 27 27 55 55 55 
5 Lactose 14 54 - 106 82 62 10 - 44 34 24 
6 Mannitol -   - 54 - - - - 62 - - - 
7 Crosspovidone - - - - - 20 20 20 10 20 30 
8 Magnesium Stearate 3 3 3 3 3 3 3 3 3 3 3 
9 Talcum 3 3 3 3 3 3 3 3 3 3 3 
10 P. Water Q.S. Q.S. Q.S. Q.S. Q.S. Q.S. Q.S. Q.S. Q.S. Q.S. Q.S. 
 Total Weight 260 260 260 260 260 260 260 260 260 260 260 
 
Total Weight of Each Bilayer Tablet was Thus 500mg for 
All prepared Formulations. 
 Pre-Compression Characteristics (2,4,7,8):  
The following parameters are determined.  
1 Angle of Repose:  
The angle of repose has been used to characterize the flow 
properties of solids. This is the maximum angle possible 
between surface of pile of powder or granules and the 
horizontal plane.  
2 Bulk Density  
The ratio of mass (weight) to volume is known as the bulk 
density of material. The bulk density is obtained by dividing 
the weight of the sample in grams by final volume in cm3.  
3 Tapped Density 
Tapped density is determined by placing a graduated 
cylinder containing a known mass of drug on a mechanical 
tapper apparatus which is operated for fixed number of taps 
(~ 100) until a powder bed volume has reached the 
minimum.  
4 Compressibility Index 
The compressibility index of the powder was determined by 
Carr’s index. The Carr’s index is determined from the tapped 
density and poured density (bulk density) as per its formula. 
5. Hausner’s Ratio 
Hausner’s ratio is determined from the ratio of tapped 
density to bulk density using its standard formula. 
 Evaluation of Post Compression Parameter: 
1) General Appearance: 
General appearance would include a number of aspects like 
size, shape, odor, taste, texture, legibility and identifying 
marks. 
2) Size and Shape: 
Different shapes and size of tablet are available in the 
market they are manufactured in order. The shape and size 
of a tablet would vary based on tooling used in the tablet 
manufacturing. In laboratory scale tablet size measured by 
the Vanier caliper. Tablet thickness should be controlled 
within ±5% variation of a standard value. 
3) Hardness: 
Tablet hardness and strength are the essential to see that 
the tablet can with the shock and stress during 
manufacturing packaging and transportation, and while 
handle by the patient. For each formulation, the hardness of 
tablet determined using the Monsanto hardness tester. 
4)  Friability: 
Friability is the test for a tablet those whether the tablet is 
stable to abrasion or not, it is tested by using Roche 
Friabilitor.  
5) Weight Variation: 
Weight variation test is performed to check that the 
manufactured tablets have a uniform weight. For a tablet to 
pass the test not more than 2 tablets should lie out of the 
specified percentage and if no tablet differ by more than two 
times the percentage limit. 
Table No. 3: Standard Limits for Weight Variation as per 
I.P. 
Sr. No. Average weight of 
Tablet (mg) 
Maximum Percentage 
difference allowed 
1 80 10 
2 80-250 7.5 
3 >250 5 
                                                     
Table No.4: Standard Limits for Weight Variation as per 
USP 
Sr. No. Average weight of 
Tablet (mg) 
Maximum Percentage 
difference allowed 
1 130/ Less 10 
2 130-324 7.5 
3 >324 5 
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6) Drug Content (2,15,16) :  
From each batch 3 tablets were weighed each containing 10 
mg of tablet were taken. Tablets were triturated in motor 
and quantity of powder equivalent to 10 mg of tablet 
powder was transferred to 100 ml volumetric flask. 
Sufficient quantity of Phosphate buffer solution PH 6.8 was 
added with shaking and volume was made up to the mark 
and filtered through whatman filter paper. Further 
dilutions were made in concentration 2, 4, 6, 8, 10ug/ml. 
then absorbance was recorded at different wavelength of 
drugs such as (Teneligliptin at 243.6 nm and Telmisartan at 
295 nm) against phosphate buffer solution PH 6.8 as a 
blank. 
7) In vitro Disintegration Time (6,14): 
In vitro disintegration time of the tablet was determined 
using USP disintegration test apparatus as per I.P. 
specifications. It is determined by using USP device which 
consisted of 6 glass tubes that are 3 inches long. Open at one 
end and held against 10 mesh screen at the bottom end of 
basket rack assembly. To test for disintegration time, one 
tablet is placed in each tube and the basket arch is 
positioned in a 1 liter basket assembly up and down. To 
compliance with the USP standard, all tablet must 
disintegrate and all particles must pass through the 10 mesh 
in the time specified. (56, 58) 
8) In vitro Dissolution Study (15,18):  
Dissolution profiles of bilayer tablets were determined using 
the USP method II with paddle speed at 50 rpm. The media 
used in dissolution apparatus was phosphate buffer PH 6.8 
(900ml) and maintained it at 37 ± 10 C. the 2ml of sample 
were withdrawn at 0, 30, 60, 90, 120, 180, 240, 300, 360, 
420 minutes time intervals.. 5ml diluted with 10ml of 
phosphate buffer solution, and analyzed at 243.6 nm and 
295nm using UV-Visible double beam spectrophotometer 
(JASCO V-630).  
Table No.5 : Procedure for Dissolution Study 
Parameters Conditions 
Dissolution media 900ml of phosphate buffer 
solution PH 6.8 
Temperature 37±10 C 
RPM 50 
Drug Content Weigh of tablet equivalent to 
500 mg  
Volume Withdrawn 2ml 
Volume made up to 10ml 
Λmax 243.6nm and 295nm. 
Dilution Factor 5 
 
9) Stability Study:  
ICH recommends carrying out stress testing on the drug 
substance to establish its inherent characteristics and 
support the solubility of the proposed analytical procedure. 
Stability study at room temperature is the method of 
determining the actual shelf life of the product. 
Unfortunately it is difficult to make an accurate expiration 
date prediction until 2-3 yrs. Of data are generated, which 
will require long shelf life conditions. Hence accelerated 
stability studied were carried out at elevated temperature 
will help to determine shelf life within a lesser period of 
time. The prepared tablets were evaluated for a period of 
one to three month as per ICH Guidelines. (58) 
 
 Biological Screening:  
A] Antidiabetic Activity- 
Experimental Procedure: The compounds extracted during 
the present work were subjected to alloxan induced 
antidiabetic activity. 
Requirements- 
Standard drug: - Metformin Hydrochloride (120mg/kg p.o. 
body weight in 0.25% CMC solution) 
Test Combinations (19,20,23) :- 
The Test combinations are taken as : 
1) Teneligliptin :- 0.01 mg/kg p.o + Telmisartan 1mg/kg p.o. 
in 0.25% MC solution, 
 2) Teneligliptin :- 0.1 mg/kg p.o + Telmisartan 1mg/kg p.o. 
in 0.25% MC solution, 
3) Teneligliptin :- 1 mg/kg p.o + Telmisartan 1mg/kg p.o. in 
0.25% MC solution  
Chemicals:-Alloxan monohydrate(150mg/kg i.p.) 
Apparatus: - Glucometer, Disposable syringe (1ml 
tuberculin syringe), feeding needles (for oral dose), 
Polypropylene cage. 
Procedure- 
Wistar rats either sex weighing between 150-200gm were 
used. The animals were housed under controlled conditions 
with standard diet and water. The animals were kept fasted 
for 24hrs with water , diabetes was induced by Alloxan 
monohydrate (120mg/kg i.p) in normal saline solution. 
A 5% dextrose solution was given in feeding bottle for a day 
to overcome early hypoglycemic phase. The blood glucose 
level was monitored by taking blood tail tip cut method on 
glucometer. 
After 72 hrs,the animals showing blood glucose level beyond 
150mg/dl were segregated and were divided into 3 
groups.viz…(i) vehicle treated group (ii) standard treated 
group, (iii) drug treated group comprised 5 subgroups for 3 
test combinations. Each group as well as subgroup 
comprised of 6 animals.The doses of combination of  
Teneligliptin and Telmisartan to be administered to wistar 
rats based on the available references of individual drugs 
was calculated. (for acute study).  
B] Blood Sample Collection From Tail Vein:-  
1) Prevent the animal by using the mechanical restraint 
device with the tail of the animal protruding. Use 
antiseptic solution to clean the area; do not rub back 
and forth to prevent  
degradation of quality of sample. Prevent the tail from 
moving with non-dominant hand and rotate ¼ turn to work 
on the lateral tail vein. 2) Align the needle parallel to the tail 
with the sloping edge of the needle to be used facing up. 
Insert needle into the tail vein starting at the tip of the tail 
(distally) i. Gently aspirate it to collect by syringe; ii. Observe 
blood flash by syringe insertion and  let the blood drip from 
needle hub into collection tube or into hematocrit tube by 
capillary action; iii. Remove the inserted needle from the 
vein and collect blood droplets in the collection tube or into 
hematocrit tube by capillary action. 3) Put gentle pressure 
with the help of gauze for just 15 to 30 seconds until 
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bleeding from the vein has stopped. If the blood does not 
stops, clotting agent can be used to stop the blood flow. 4) 
Throw or dispose the needle well. If the animal is 
administered with an anesthetia, monitor the animal till it is 
fully awake and it is able to move normally. Repetitive 
bleeds for blood collection may be performed by insertion of 
the needle further up the tail. 
 
C] Methodology:-Collection of Blood:- 
Table no. 6 Biological activity profile table (A1, B1, C1 are doses of Teneligliptin and A2, B2, C2 are doses of 
Telmisartan respectively. 
Sr.No.       Groups 
       ( N=6) 
Treatment and dose day Observation 
 
1 Group-I Vehicle control( 1ml saline water p.o.) 0 to 28 day. 1) Estimation of 
blood glucose level on 
2nd,4th,6th, 8th,10th and 
28th days. 
2) Stastistical analysis 
by ANOVA followed by 
Dunnett’s test. 
 
2 Group-II Negative control Alloxan monohydrate(150mg/kg i.p.) for 0 to 2 days 
3 Group-III Positive control Alloxan Monohydrate(150mg/kg) for 2 days + 
Metformin hydrochloride(50mg/kg) p.o. for next 26 days.  
4 Group-IV Alloxan monohydrate(150mg/kg) i.p.+ test  drugs A1(0.1mg/kg) + 
A2(1mg/kg) p.o. 
5 Group-V Alloxan monohydrate(150mg/kg) i.p+ test  drugs B1(1mg/kg) + 
B2(1mg/kg) p.o 
6 Group-VI Alloxan monohydrate (150mg/kg) i.p+ test  drugs C1(10mg/kg) + 
C2(1mg/kg) p.o. 
 
RESULTS AND DISCUSSION: 
IR Spectroscopy Analysis: 
 The IR Spectrum of the drug agrees with its chemical structure 6-chloro-4hydroxy-2-methyl-N-2-pyridyl-2H-thieno-[2, 3 
 
Figure No. 1: Infrared Spectrum of Teneligliptin 
Table No. 7: IR Peak Value of Teneligliptin 
Sr. No. Absorption 
Peak cm-1 
Attributed to 
Functional Group 
Type of Vibrations 
1.  3447.13 N-H Stretching 
2.  2956.87 C-H Stretching 
3.  1571.7 C-C Stretching 
4.  692.32 C-S Stretching 
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The IR Spectrum of the drug agree with the chemical structure (RS)-2-(3-benzoylphenyl)-propionic acid.  
 
Figure No.2: Infrared Spectrum of Telmisartan 
Table No. 8: IR Peak Value of Telmisartan 
Sr. 
No. 
Absorption Peak 
cm-1 
Attributed to 
Functional Group 
Type of Vibrations 
1.  3151.11 C-H Stretching 
2.  1476.24 C=C Stretching 
3.  999.91 C-N Stretching 
  
 
Figure No. 3: IR Spectrum of Teneligliptin and Telmisartan Mixture with Polymers 
Table No. 9: IR Value of Teneligliptin and Telmisartan Mixture with Polymers 
Types of Bonds   Wave Number /cm-1   
Found  
N-H Stretching  3456.78  
C-H Stretching (Methyl)  2970.8  
C-H Stretching Vibration of (aromatic ring)  3114.47  
C=O Stretching Vibration of Amide Moiety  1650.77  
Aliphatic C-H Stretch  2962.13  
CH2 (Bending)  1461.78  
C=C Stretching/bending  1599.66  
COOH bending  1381.75  
COOH Acid  1696.09  
Disubstituted benzene  741.496 
758.852  
C-N Stretching  1265.07  
C-S  694.248  
 
The peaks observed in pure samples of Teneligliptin and 
Telmisartan drugs sample determined by IR analysis are one 
and same as the reference graph. The peaks observed in the 
IR graph of the mixture sample of Teneligliptin and 
telmisartan with the polymers  which are used in the 
formulation are in same position / state as that of the IR 
Spectrum of pure sample. 
Thus justified that there is no or minimal interaction of 
binders with the drug molecules. Hence there is no obstacle 
in using these binders to formulate the tablet. 
5. Differential Scanning Calorimetry: 
The DSC thermogram of Teneligliptin showed a sharp 
exothermic peak at 210.60C. Telmisartan exhibited single, 
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sharp endothermic peak at 275.60C. The obtained values are 
much close to reported value of Teneligliptin and 
Telmisartan Melting Point. The Teneligliptin and telmisartan 
bilayer Tablet Formulation exhibited double, sharp 
endothermic peaks at 355.430C, 260.730C and 170.910C.
 
 
Figure No. 4: DSC Graph of Teneligliptin                                 Figure No. 5: DSC Graph of Telmisartan 
 
Figure No. 6: DSC Graph of Teneligliptin and Telmisartan Bilayer Tablet Formulation 
 
6. Calibration Curve of Teneligiptin: 
The standard calibration curve shows the slope of 0.065 and 
correlation coefficient of 0.998. The curve was found to be 
linear in the concentration range of 2, 4, 6, 8, 10μg/ml at 
243.6 nm. The calculation of drug content, in vivo 
dissolution study was based on the calibration curve. 
Table No. 10: Calibration Curve of Teneligliptin 
Sr. 
No. 
Concentration 
(μg/ml) 
Absorbance at  
243.6 nm 
1.  0 0 
2.  10 0.1991 
3.  20 0.3871 
4.  30 0.5928 
5.  40 0.7876 
6.  50 0.9578 
 
 
Figure No. 7: Calibration Curve of Teneligliptin 
 
Figure No. 8: UV Spectrum of Teneligliptin 
Tablet No. 11: UV Parameter for calibration curve in pH 
6.8 buffer solution 
Sr. 
No. 
Parameters Value in pH 6.8 
phosphate buffer 
solution 
1 Absorbance 
maximum (λmax) in 
nm 
243.6nm 
2 Slope 0.0193 
3 Intercept 0.0046 
4 Correlation 
Coefficient 
0.9994 
5 Equation Y= 0.0193X + 0.0046 
 
 
y = 0.0193x + 0.0046 
R² = 0.9994 
0
0.2
0.4
0.6
0.8
1
1.2
0 20 40 60
Series1
Linear (Series1)
conc 
a
b
s 
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7. Calibration Curve of Telmisartan: 
The standard calibration curve of Telmisartan was obtained 
by plotting Absorbance vs. Concentration. Table No. 12 
shown the absorbance values of Telmisartan. The standard 
curve is shown in Figure 9.9. The standard calibration curve 
shows the slope of 0.075 and correlation coefficient of 0.996. 
The curve was found to be linear in the concentration range 
of 2, 4, 6, 8, 10μg/ml at 295 nm. The calculation of drug 
content, in vivo dissolution study was based on the 
calibration curve. 
Table No. 12: Calibration Curve of Telmisartan 
Sr. No. Concentration (μg/ml) Absorbance at  
295 nm 
1.  0 0 
2.  2 0.136 
3.  4 0.2553 
4.  6 0.3794 
5.  8 0.5151 
6.  10 0.6471 
 
 
Figure No. 9: Calibration Curve of Telmisartan 
 
Figure No. 10: UV Spectrum of Telmisartan 
 
Tablet No. 13: UV Parameter for calibration curve in pH 
6.8 buffer solution 
Sr.No. Parameters Value in pH 6.8 
phosphate buffer 
solution 
1 Absorbance maximum 
(λmax) in nm 
295nm 
2 Slope 0.0642 
3 Intercept 0.001 
4 Correlation Coefficient 0.9996 
5 Equation Y= 0.0642X+ 0.001 
 
Characterization of Granules of API and Excipients: 
For each type of preliminary formulation blends, blends of 
API and Excipients were prepared and evaluated for various 
parameters as explained earlier. 
 
Table No.14: Characterization of Telmisartan Granules :- 
Formulation 
Batches 
Evaluation Parameters 
Angle of 
Repose 
Bulk Density 
(gm/cm3) 
Tapped 
Density 
(gm/cm3) 
Compressibility 
Index (%) 
Hausner 
Ratio 
F1 27.490 0.67 0.75 10.66 1.11 
F2 24.730 0.72 0.79 8.86 1.09 
F3 25.330 0.75 0.83 9.63 1.10 
F4 25.690 0.77 0.81 4.93 1.05 
F5 27.350 0.69 0.75 8.00 1.08 
F6 25.370 0.76 0.82 7.31 1.070 
F7 26.230 0.78 0.84 7.14 1.076 
F8 24.820 0.66 0.72 8.33 1.09 
F9 26.470 0.70 0.75 6.66 1.071 
F10 25.840 0.71 0.78 8.97 1.09 
F11 26.770 0.75 0.80 6.25 1.06 
 
 
 
y = 0.0642x + 0.001 
R² = 0.9996 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0 5 10 15
Series1
Linear (Series1)
conc 
a
b
s 
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Table No.15:- Characterization of Teneligliptin Granules :- 
Formulation 
Batches 
Evaluation Parameters 
Angle of 
Repose 
Bulk Density 
(gm/cm3) 
Tapped Density 
(gm/cm3) 
Compressibility 
Index (%) 
Hausner 
Ratio 
F1 25.390 0.63 0.68 7.35 1.07 
F2 22.460 0.65 0.71 8.45 1.09 
F3 24.850 0.71 0.75 5.33 1.05 
F4 23.490 0.72 0.77 6.4 1.06 
F5 25.150 0.68 0.70 2.85 1.02 
F6 26.610 0.75 0.79 5.06 1.05 
F7 23.530 0.66 0.73 9.58 1.10 
F8 24.110 0.64 0.69 7.24 1.07 
F9 22.360 0.69 0.75 8.00 1.08 
F10 22.560 0.71 0.76 6.57 1.07 
F11 23.530 0.70 0.77 9.09 1.10 
 
 Evaluation of Compressed Tablets: 
All the tablet formulation were subjected for Organoleptic, Physical and Chemical evaluation as shape. Thickness, Hardness, 
Friability, Weight Variation, In-vitro Disintegration Time, Drug Content, And In-vitro Dissolution Studies. 
Table No.16: Evaluation of Formulated Batches 
 
 
 
 
 
 
 
 
 
 
Table No.17: Evaluation of Post-Formulated Batches 
Sr. No Formulations Diameter 
(mm ± SD) 
Disintegration 
Time (min.) 
% Drug Content % Drug Release in 
(420 mins.) 
1 F1 10±0.00 62 min Teneligliptin 96.13 23.2 
Telmisartan 95.20 20.53 
2 F2 10±0.00 71 min Teneligliptin 97.48 19.03 
Telmisartan 95.63 14.70 
3 F3 10±0.00 76 min Teneligliptin 96.32 35.61 
Telmisartan 96.65 27.32 
4 F4 10±0.00 87 mins Teneligliptin 97.23 22.65 
Telmisartan 96.35 15.32 
5 F5 10±0.00 69 mins Teneligliptin 98.75 23.78 
Telmisartan 99.27 18.55 
6 F6 10±0.00 110 mins Teneligliptin 98.58 49.45 
Telmisartan 98.72 43.81 
7 F7 10±0.00 79 mins Teneligliptin 96.54 29.05 
Telmisartan 96.23 25.30 
8 F8 10±0.00 115 mins Teneligliptin 95.81 38.28 
Telmisartan 96.75 31.10 
9 F9 10±0.00 92 mins Teneligliptin 97.38 23.48 
Telmisartan 96.87 19.42 
10 F10 10±0.00 107 mins Teneligliptin 98.41 42.41 
Telmisartan 99.15 40.48 
11 F11 10±0.00 96 mins Teneligliptin 97.36 15.88 
Telmisartan 96.25 10.96 
Sr. 
No. 
Formulations Thickness 
(mm ± SD) 
Hardness 
(kg/cm2) 
Friability 
(%) 
Weight Variation (mg ± 
SD) 
1 F1 3.49  4.23 0.57 497 ± 0.75 
2 F2 3.30         4.45 0.45 494 ± 0.50 
3 F3 3.25         4.67 0.61 498 ± 0.75 
4 F4 3.29 4.98 0.71 496± 0.50 
5 F5 3.75 5.19 0.41 491± 0.75 
6 F6 3.43 4.71 0.67 499± 0.50 
7 F7 3.37 4.55 0.83 501± 0.50 
8 F8 3.63 5.10 0.57 495± 0.75 
9 F9 3.26 4.81 0.91 503± 0.75 
10 F10 3.88 4.38 0.48 492± 0.50 
11 F11 3.54 4.73 0.84 498± 0.50 
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Table No.18: Comparative %Drug Release of Bathes (Teneligliptin) 
Sr. No. Time (min) F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 
1 0 0 0 0 0 0 0.00 0 0 0 0 0 
2 60 4.46 2.74 10.16 3.55 3.74 13.48 5.29 11.23 2.28 12.56 2.64 
3 120 7.23 5.39 16.21 6.88 7.35 18.02 8.36 16.22 5.27 19.87 3.45 
4 180 10.45 8.36 20.23 10.51 10.54 25.20 12.87 20.65 9.34 24.54 5.36 
5 240 13.81 11.65 24.41 13.06 12.54 31.69 15.32 25.17 12.36 29.36 8.74 
6 300 17.35 14.98 27.87 15.56 15.67 38.56 21.36 29.34 15.23 33.45 11.54 
7 360 20.15 17.05 31.56 19.32 19.65 43.76 27.65 33.54 18.65 38.54 13.65 
8 420 23.35 19.03 35.61 22.65 23.78 49.45 29.05 38.28 23.48 42.41 15.88 
 
 
 
Figure No.11 : Comparative Dissolution Profile of All Batches (Teneligliptin) 
 
Table No.19: Comparative %Drug Release of Bathes (Telmisartan) 
Sr. No. 
Time 
(min.) F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 
0 0 0 0 0 0 0 0.00 0 0 0 0 0 
1 60 5.23 1.2 5.79 2.87 0.77 7.62 2.63 9.25 3.96 13.48 0.89 
3 120 8.66 3.7 9.52 4.98 2.37 11.06 5.98 13.65 5.47 19.56 1.23 
4 180 11.56 5.5 13.85 7.22 5.56 16.71 9.23 18.36 8.56 24.32 2.84 
5 240 14.25 7.4 17.69 9.36 8.74 23.28 12.34 20.96 11.91 29.89 3.95 
6 300 16.32 9.8 21.54 11.87 11.54 29.63 17.36 24.38 14.21 34.13 6.26 
7 360 18.58 12.6 24.35 13.21 15.23 37.96 21.03 28.36 16.69 37.33 8.45 
8 420 20.53 14.7 27.32 15.32 18.55 43.81 25.3 31.1 19.42 40.48 10.96 
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Figure No.12: Comparative Dissolution Profile of All Batches (Telmisartan) 
 
 Stability Study: 
Stability studies of the Best Formulation F6 was carried out 
by keeping the tablets at room temperature and 400C ±20 C/ 
75 ±5 % RH (stability chamber) for 30 days. From the 
stability studies it was found that formulation were stable at 
room temperature and 400C ±20 C/ 75 ±5 % RH for a period 
of 60 days. There was no appreciable and highlighting 
change in physical properties, drug release and drug content 
during the testing period. Thus the test indicated stability of 
formulations. 
1. Physical Appearance: 
Color: unchanged.   Odour: unchanged 
 
Table No. 20: Stability Parameters of F6 for 0, 30, 60 Days 
Formulations Study 
Conditions 
Specification 
Months Drugs Name % Drug 
Content 
% Drug 
Release 
F6 400C ±20 C/ 75 
±5 % RH 
Initial Teneligliptin 98.58 49.45 
Telmisartan 98.72 43.81 
30 days Teneligliptin 98.21 48.64 
Telmisartan 98.44 42..37 
60days Teneligliptin 97.73 47.58 
Telmisartan 97.84 41.46 
 
 Biological screening 
 Animal study:-  
Table No.21:- Body weight of albino rats before and after treatment:- 
Sr.No Body wt. before treatment Body wt. after end of the treatment 
Negative Control 241±1.40 229±1.63 
Positive Control 240±1.44 242±1.67 
Std 220±1.88 210±1.78 
4a 260±2.45 255±2.56 
4b 250±2.76 262±2.67 
4c 250±1.78 270±2.78 
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Table no. 22:- Blood glucose level 
Drug Blood glucose level mg/dl (Mean ± SEM) 
0 days 2 days 4 days 6 days 8 days 
Negative control 232±2.31 233±2.97 231±1.24 233±2.86 230±2.46 
Positive control 115±1.44 116±2.67 118±1.45 114±2.45 115±2.45 
Standard 204±2.28 118±2.21 153±1.99 128±2.27 116±1.51 
4a 215±4.55 190±4.78 151±1.23 137±1.90 119±3.64 
4b 205±3.54 194±2.67 162±2.89 133±1.43 128±3.51 
4c 222±1.89 203±1.78 157±2.45 142±1.97 130±1.09 
 
The antidiabetic activity is held and by the observation of 
blood glucose levels we can say that the Teneligliptin and 
Telmisartan Combination is useful in the activity. 
CONCLUSION: 
On the basis of the study, selection of drug candidate and the 
type of formulation lead to the formulation of Bilayer Tablets 
to treat Co-existent Type II Diabetes Mellitus and 
Hypertension were formulated successfully. The addition of 
magnesium stearate which produce satisfactory results for 
flow property of powders. Addition of crospovidone 
improved drug release of    Telmisartan layer. The 
Preformulation study revealed the purity of drug and also it 
confirmed the stability of drug with excipient hence proved 
to be compatible there.  
All the tablet formulations showed satisfactory results with 
respect to hardness, friability, disintegration time, drug 
content and In-vitro dissolution studies. The binder, filler, 
diluents, lubricants used in the formulations which improve 
the tablet quality and sustained release agent improve the 
disintegration and dissolution property of tablets. The 
powder was granulated by wet granulation and the second 
layer was compressed above the compressed first layer, it is 
a good method used for the compression of bilayer tablets. 
Wet granulation is the best method for formulation of such 
bilayer tablets. The results obtained in Biological Studies 
revealed that the present drug combination shows 
antidiabetic activity. Telmisartan does not hinders the 
antidiabetic activity of Teneligliptin when taken in 
combination. Thus, there is no Drug-Drug Interaction 
between Teneligliptin and Telmisartan. Therefore, this 
research work concludes the successful was shown the 
“Formulation and Evaluation of Teneligliptin and 
Telmisartan Bilayer Tablets for the Treatment of Coexistent 
Type II Diabetes Mellitus and Hypertension”. 
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